Latest News
Penn Medicine’s Carl June, MD, to Receive 2024 Breakthrough Prize in Life Sciences
CAR T cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies (CCI) at Penn Medicine’s Abramson Cancer Center, has been named a winner of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor (CAR) T cell immunotherapy, a revolutionary cancer treatment approach in which each patient’s T cells are modified to target and kill their cancer cells. The invention sparked a new path in cancer care, harnessing the power of patients’ own immune systems, a once-elusive goal that brought fresh options for those who could not be successfully treated with conventional approaches.
Cancer cell therapy pioneer Carl June receives the 2020 Sanford Lorraine Cross Award
World-renowned cancer cell therapy pioneer Carl June, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, received the $1 million Sanford Lorraine Cross Award for his groundbreaking work in developing chimeric antigen receptor (CAR) T cell therapy.
Penn Medicine cancer cell therapy pioneer Carl June named 2021 Dan David Prize Laureate
International cancer cell therapy pioneer Carl June, the Richard W. Vague professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, has been named a 2021 Dan David Prize Laureate.
The Dan David Prize is endowed by the Dan David Foundation, headquartered at Tel Aviv University, which annually awards three prizes of $1 million each to globally inspiring individuals and organizations, honoring outstanding contributions that expand knowledge of the past, enrich society in the present, and promise to improve the future of the world.
https://penntoday.upenn.edu/news/penn-medicine-cancer-cell-therapy-carl-june-2021-dan-david-prize
Penn Medicine's Carl June Receives 2018 Albany Prize
August 15, 2018
June is recognized for his work in pioneering the development of CAR T therapy for cancer
PHILADELPHIA – Carl June, MD, a gene therapy pioneer at the Abramson Cancer Center of the University of Pennsylvania, will receive the 2018 Albany Medical Center Prize in Medicine and Biomedical Research. June is receiving the award for his pioneering work in developing CAR T therapy, which became the nation's first FDA-approved personalized cellular therapy for cancer in August 2017 and was approved for additional indications earlier this year. The prize will be awarded during a celebration on Wednesday, Sept. 26, in Albany, New York.
Albany Medical Center has given out the $500,000 award annually since 2001 to those “who have altered the course of medical research” and is one of the largest prizes in medicine and science in the United States, according to the organization. June is one of three scientists who will receive this year’s award. The others are Steven A. Rosenberg, MD, PhD, chief of the Surgery Branch of the Center for Cancer Research at the National Cancer Institute, and James P. Allison, PhD, chair of Immunology at the University of Texas MD Anderson Cancer Center.
CAR T Receives FDA Approval!!
9/28/2017
Now4Lymphoma2- FDA APPROVES KYMRIAH FOR TREATMENT OF LYMPHOMA!
5/1/2018
Congratulations to Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research and Director of the Lymphoma Program at Penn’s Abramson Cancer Center and Carl June for recent FDA Approval of Kymriah for Lymphoma!
Full article available to learn more about these recent advancements
